Voyager Therapeutics (VYGR) Projected to Post Quarterly Earnings on Monday

Voyager Therapeutics (NASDAQ:VYGR) is projected to issue its Q3 2026 resultson Monday, November 9th. Analysts expect Voyager Therapeutics to announce earnings of ($0.41) per share and revenue of $6.35 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. The firm had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. On average, analysts expect Voyager Therapeutics to post ($1.63) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

Voyager Therapeutics Price Performance

VYGR stock opened at $1.72 on Monday. Voyager Therapeutics has a 52 week low of $1.68 and a 52 week high of $5.48. The company has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $3.46. The firm has a market capitalization of $105.98 million, a P/E ratio of -0.96 and a beta of 1.28.

Analysts Set New Price Targets

VYGR has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.